AstraZeneca's Invitrogen approved in China

2025-06-04 17:00:09

On June 4, AstraZeneca announced that Imfinzi (generic name: Durvalumab) has been approved by the China National Medical Products Administration (NMPA) as a single agent for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) who have not experienced disease progression after platinum-based chemoradiotherapy.

AstraZeneca

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Air India flight returns after takeoff due to technical issues
                            2025-06-16

                                    Southbound funds made a large net purchase of 5.743 billion yuan today. In terms of Hong Kong Stock Connect (Shanghai), China Construction Bank and Meituan-W received net purchases of HK$1.108 billion and HK$493 million respectively; Xiaomi Group-W ranked first in net sales, with an amount of HK$1.489 billion; in terms of Hong Kong Stock Connect (Shenzhen), Meituan-W and Kangfang Biopharma received net purchases of HK$622 million and HK$206 million respectively; Xiaomi Group-W ranked first in net sales, with an amount of HK$391 million.
                            2025-06-16

                                    Arm (ARM.O): We are better than Nvidia on a wider range of platforms.
                            2025-06-12

                                    Lei Jun: Xiaomi Yu7 will be released at the end of June
                            2025-06-16

                                    Putin: Russia will create unmanned system forces as a separate branch of the military
                            2025-06-13